Organon OGN Other Cardiovascular — Revenue

Other product segments

Similar metrics at other companies

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

URIServiceand Other Revenues — Revenue

$101M+6.3%

FLYWPlatform And Other Revenues — Revenue

$31.85M+1.7%

COINOther revenue — Revenue

$73.63M-24.5%

FAQ

What is Organon's other cardiovascular — revenue?

Organon (OGN) reported other cardiovascular — revenue of $28M in Q1 2026.

How has Organon's other cardiovascular — revenue changed year-over-year?

Organon's other cardiovascular — revenue decreased by 6.7% year-over-year, from $30M to $28M.

What is the long-term trend for Organon's other cardiovascular — revenue?

Over 4 years (2021 to 2025), Organon's other cardiovascular — revenue has grown at a -10.2% compound annual growth rate (CAGR), from $192M to $125M.

What does other cardiovascular — revenue mean?

This metric represents the total net sales generated from the company's portfolio of cardiovascular pharmaceutical products that fall outside of its primary or lead therapeutic franchises. It reflects the market demand and commercial performance of these established or secondary cardiovascular therapies within the broader product mix. Monitoring this revenue stream helps investors assess the contribution and lifecycle maturity of the company's secondary cardiovascular assets.